MA41988A - Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa - Google Patents

Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa

Info

Publication number
MA41988A
MA41988A MA41988A MA41988A MA41988A MA 41988 A MA41988 A MA 41988A MA 41988 A MA41988 A MA 41988A MA 41988 A MA41988 A MA 41988A MA 41988 A MA41988 A MA 41988A
Authority
MA
Morocco
Prior art keywords
azabenzimidazoles
receiver modulators
ampa
ampa receiver
compounds
Prior art date
Application number
MA41988A
Other languages
English (en)
Other versions
MA41988B1 (fr
Inventor
Michael K Ameriks
Cynthia G B Berry
Gang Chen
Fabrice Loic Jourdan
Terry Patrick Lebold
David Wei Lin
Piñón Miguel Angel Pena
Suchitra Ravula
Bradley M Savall
Devin M Swanson
Dongpei Wu
Wei Zhang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA41988A publication Critical patent/MA41988A/fr
Publication of MA41988B1 publication Critical patent/MA41988B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention porte sur des composés de formule (l) et sur leurs sels, n-oxydes et solvates, de qualité pharmaceutique. L'invention concerne également des compositions pharmaceutiques comprenant des composés de formule (i), et des méthodes d'utilisation de ces composés de formule (i).
MA41988A 2015-04-29 2016-04-28 Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa MA41988B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154313P 2015-04-29 2015-04-29
PCT/US2016/029801 WO2016176460A1 (fr) 2015-04-29 2016-04-28 Azabenzimidazoles et leur utilisation en tant que modulateurs des récepteurs ampa

Publications (2)

Publication Number Publication Date
MA41988A true MA41988A (fr) 2018-07-03
MA41988B1 MA41988B1 (fr) 2021-03-31

Family

ID=56008859

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41988A MA41988B1 (fr) 2015-04-29 2016-04-28 Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa

Country Status (39)

Country Link
US (4) US11312712B2 (fr)
EP (3) EP4144736A1 (fr)
JP (2) JP6800886B2 (fr)
KR (2) KR20170140382A (fr)
CN (1) CN107835814B (fr)
AR (1) AR104447A1 (fr)
AU (2) AU2016255434C1 (fr)
BR (2) BR112017023147B1 (fr)
CA (1) CA2983826A1 (fr)
CO (1) CO2017011017A2 (fr)
CR (1) CR20170484A (fr)
CY (1) CY1124059T1 (fr)
DK (1) DK3288940T5 (fr)
EA (1) EA033281B1 (fr)
EC (1) ECSP17074645A (fr)
ES (1) ES2865330T3 (fr)
GT (1) GT201700231A (fr)
HK (1) HK1252249A1 (fr)
HR (1) HRP20210403T1 (fr)
HU (1) HUE053943T2 (fr)
IL (1) IL254848B (fr)
JO (1) JO3654B1 (fr)
LT (1) LT3288940T (fr)
MA (1) MA41988B1 (fr)
MD (1) MD3288940T2 (fr)
MX (1) MX2017013886A (fr)
MY (1) MY194104A (fr)
NI (1) NI201700129A (fr)
PH (1) PH12017501816A1 (fr)
PL (1) PL3288940T3 (fr)
PT (1) PT3288940T (fr)
RS (1) RS61688B1 (fr)
SG (1) SG11201708190UA (fr)
SI (1) SI3288940T1 (fr)
TW (1) TWI706952B (fr)
UA (1) UA120304C2 (fr)
UY (1) UY36654A (fr)
WO (1) WO2016176460A1 (fr)
ZA (1) ZA201708065B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023038A2 (pt) * 2015-04-29 2018-07-03 Janssen Pharmaceutica Nv imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
CN111315735B (zh) * 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
EP3693360B1 (fr) * 2017-10-06 2023-12-13 Takeda Pharmaceutical Company Limited Composés hétérocycliques
RS65335B1 (sr) 2018-10-05 2024-04-30 Annapurna Bio Inc Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj
EP3873905A4 (fr) * 2018-10-30 2022-08-17 Repare Therapeutics Inc. Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr
KR20220035925A (ko) * 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
US20240076285A1 (en) * 2020-12-16 2024-03-07 Shankar Venkatraman Compounds and compositions for treating conditions associated with sting activity
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN115304599A (zh) * 2022-09-20 2022-11-08 浙大宁波理工学院 一种3-溴-6-异丙基-1氢-哌咯[2,3-b]并吡啶及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
CN1051313A (zh) 1990-11-07 1991-05-15 鞍山市振东工业尼龙厂 尼龙球磨罐及其热装工艺
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
TW251284B (fr) 1992-11-02 1995-07-11 Pfizer
CA2183084A1 (fr) 1994-02-10 1995-08-17 John Eugene Macor Derives du 5-heteroarylindole
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
EP1100504A2 (fr) * 1998-07-02 2001-05-23 Eisai Co., Ltd. Compositions pharmaceutiques et leur utilisation
JP2002533360A (ja) 1998-12-31 2002-10-08 スージェン・インコーポレーテッド 蛋白質キナーゼ活性を調節するためおよび癌の化学療法において用いるための3−ヘテロアリーリデニル−2−インドリノン化合物
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
EP1309577A2 (fr) 2000-08-11 2003-05-14 Eli Lilly And Company Derives sulfonamides heterocycliques
US6548576B1 (en) 2001-11-07 2003-04-15 Bourns, Inc. Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
EA012178B1 (ru) 2004-09-03 2009-08-28 Лаборатуар Сероно Са Пиридинметиленазолидиноны и их применение
AU2006296369B2 (en) 2005-09-30 2012-12-20 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
WO2007135529A2 (fr) * 2006-05-23 2007-11-29 Pfizer Products Inc. Composés d'azabenzimidazolyle
JP2010508328A (ja) 2006-11-03 2010-03-18 グラクソ グループ リミテッド Ampa受容体を強化する化合物および医薬におけるその使用
WO2008113795A1 (fr) 2007-03-20 2008-09-25 Glaxo Group Limited Composés potentialisant le récepteur ampa et leurs utilisations en médecine
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (fr) 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinaisons d'inhibiteurs de pde4 et d'antipsychotiques pour le traitement de troubles psychotiques
WO2009073777A1 (fr) 2007-12-06 2009-06-11 Schering Corporation Modulateurs de la gamma sécrétase
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
WO2010005528A2 (fr) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Dérivés acide carboxylique de pyrrolopyridine
GB0822425D0 (en) 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (fr) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Composés hétérocycliques substitués
WO2011156245A2 (fr) * 2010-06-09 2011-12-15 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs de mglur2
AR082618A1 (es) 2010-08-10 2012-12-19 Takeda Pharmaceutical Derivados de tiadiazina, composiciones farmaceuticas y usos
EP2603079B1 (fr) 2010-08-12 2018-09-19 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs de mglur2
WO2013064984A1 (fr) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryléthersulfonamides et leur utilisation en tant qu'agents thérapeutiques
WO2013130501A1 (fr) 2012-03-01 2013-09-06 The Board Of Regents Of The University Of Texas System Modulateurs bivalents allostériques positifs des récepteurs ampa
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios

Also Published As

Publication number Publication date
EP3901153A1 (fr) 2021-10-27
ECSP17074645A (es) 2018-02-28
EP3288940B9 (fr) 2021-07-21
EP3288940A1 (fr) 2018-03-07
PL3288940T3 (pl) 2021-07-12
US20230114165A1 (en) 2023-04-13
UY36654A (es) 2016-10-31
DK3288940T5 (da) 2021-09-20
JP2018518462A (ja) 2018-07-12
BR112017023147B1 (pt) 2024-04-30
EA033281B1 (ru) 2019-09-30
HK1252249A1 (zh) 2019-05-24
EP4144736A1 (fr) 2023-03-08
US20180118740A1 (en) 2018-05-03
CY1124059T1 (el) 2022-05-27
AU2020210231A1 (en) 2020-08-20
UA120304C2 (uk) 2019-11-11
DK3288940T3 (da) 2021-05-25
US20210284641A1 (en) 2021-09-16
CA2983826A1 (fr) 2016-11-03
CO2017011017A2 (es) 2018-03-20
IL254848B (en) 2021-01-31
NZ736057A (en) 2023-08-25
RS61688B1 (sr) 2021-05-31
AU2016255434B2 (en) 2020-05-14
MX2017013886A (es) 2018-03-12
JP2021042230A (ja) 2021-03-18
ZA201708065B (en) 2019-09-25
MY194104A (en) 2022-11-11
LT3288940T (lt) 2021-05-10
CR20170484A (es) 2018-02-26
MD3288940T2 (ro) 2021-08-31
MA41988B1 (fr) 2021-03-31
AU2020210231B2 (en) 2021-07-22
JP7026194B2 (ja) 2022-02-25
NI201700129A (es) 2019-05-10
PH12017501816A1 (en) 2018-04-23
EP3288940B1 (fr) 2021-02-24
JP6800886B2 (ja) 2020-12-16
IL254848A0 (en) 2017-12-31
CN107835814B (zh) 2021-07-23
GT201700231A (es) 2018-12-20
KR20240017991A (ko) 2024-02-08
JO3654B1 (ar) 2020-08-27
TW201708217A (zh) 2017-03-01
SG11201708190UA (en) 2017-11-29
BR122023023802A2 (pt) 2023-12-26
PT3288940T (pt) 2021-04-30
EA201792374A1 (ru) 2018-05-31
AR104447A1 (es) 2017-07-19
AU2016255434A1 (en) 2017-10-26
KR20170140382A (ko) 2017-12-20
SI3288940T1 (sl) 2021-07-30
TWI706952B (zh) 2020-10-11
US11312712B2 (en) 2022-04-26
BR112017023147A2 (pt) 2018-07-10
WO2016176460A1 (fr) 2016-11-03
US20230110576A1 (en) 2023-04-13
HUE053943T2 (hu) 2021-08-30
ES2865330T3 (es) 2021-10-15
CN107835814A (zh) 2018-03-23
AU2016255434C1 (en) 2021-09-23
HRP20210403T1 (hr) 2021-10-29

Similar Documents

Publication Publication Date Title
MA41988A (fr) Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
PH12015501720A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX363392B (es) Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos.
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
GEP20156318B (en) Heteroaryl derivatives as alpha7 nachr modulators
AU2018253590A1 (en) Imidazopyridazine compounds
MA46490A1 (fr) Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués
MX2014014832A (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa.
TW201613864A (en) Novel compounds
EA201992679A1 (ru) N-замещенные индольные производные
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MX2018015872A (es) Derivados de benzodioxano y su uso farmaceutico.
NZ756915A (en) Dual magl and faah inhibitors
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
PH12016501625A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
PH12016500312A1 (en) 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
MX369806B (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
TN2018000175A1 (en) Indane derivatives as mglur7 modulators